JP2024546569A5 - - Google Patents
Info
- Publication number
- JP2024546569A5 JP2024546569A5 JP2024524692A JP2024524692A JP2024546569A5 JP 2024546569 A5 JP2024546569 A5 JP 2024546569A5 JP 2024524692 A JP2024524692 A JP 2024524692A JP 2024524692 A JP2024524692 A JP 2024524692A JP 2024546569 A5 JP2024546569 A5 JP 2024546569A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical product
- product according
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163265438P | 2021-12-15 | 2021-12-15 | |
| US63/265,438 | 2021-12-15 | ||
| PCT/US2022/081596 WO2023114875A1 (en) | 2021-12-15 | 2022-12-14 | Wee1 inhibitor for cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024546569A JP2024546569A (ja) | 2024-12-26 |
| JP2024546569A5 true JP2024546569A5 (https=) | 2025-12-23 |
Family
ID=86773533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024524692A Pending JP2024546569A (ja) | 2021-12-15 | 2022-12-14 | がんに対するｗｅｅ１阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240335447A1 (https=) |
| EP (1) | EP4447974A4 (https=) |
| JP (1) | JP2024546569A (https=) |
| KR (1) | KR20240119059A (https=) |
| CN (1) | CN118201616A (https=) |
| AU (1) | AU2022414090A1 (https=) |
| CA (1) | CA3235595A1 (https=) |
| MX (1) | MX2024004157A (https=) |
| WO (1) | WO2023114875A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020384291A1 (en) | 2019-11-15 | 2022-05-26 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| WO2022011391A1 (en) | 2020-07-09 | 2022-01-13 | Recurium Ip Holdings, Llc | Salts and forms of a wee1 inhibitor |
| WO2025184572A1 (en) * | 2024-03-01 | 2025-09-04 | Zeno Management, Inc. | Wee1 inhibitor combination therapy |
| WO2025261307A1 (zh) * | 2024-06-17 | 2025-12-26 | 首药控股(北京)股份有限公司 | 治疗肿瘤的药物组合及用途 |
| CN121159528A (zh) * | 2025-07-25 | 2025-12-19 | 天津医科大学总医院 | 一种PROTAC化合物及其制备方法和作为靶向PTRF/Cavin1的降解剂的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017003502A1 (en) * | 2015-07-01 | 2017-01-05 | Dignity Health | Systems and methods for treating cancer |
| EP4566612A3 (en) * | 2018-03-09 | 2025-08-20 | Recurium IP Holdings, LLC | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
-
2022
- 2022-12-14 EP EP22908681.4A patent/EP4447974A4/en active Pending
- 2022-12-14 CN CN202280073343.3A patent/CN118201616A/zh active Pending
- 2022-12-14 AU AU2022414090A patent/AU2022414090A1/en active Pending
- 2022-12-14 CA CA3235595A patent/CA3235595A1/en active Pending
- 2022-12-14 WO PCT/US2022/081596 patent/WO2023114875A1/en not_active Ceased
- 2022-12-14 KR KR1020247013738A patent/KR20240119059A/ko active Pending
- 2022-12-14 JP JP2024524692A patent/JP2024546569A/ja active Pending
- 2022-12-14 MX MX2024004157A patent/MX2024004157A/es unknown
-
2024
- 2024-06-14 US US18/743,544 patent/US20240335447A1/en active Pending